Scientific Progress Involves Research Findings With Missed End Points.

Citation metadata

From: Oncology(Vol. 35, Issue 9)
Publisher: Intellisphere, LLC
Document Type: Article
Length: 579 words
Lexile Measure: 1810L

Document controls

Main content

Article Preview :

Regular consumers of scientific journals are often presented with a picture of trials or studies with highly statistically significant data rejecting the null hypothesis and potentially practice-changing implication in its wake.

In this month's issue, original research from Bethany Smith, PhD, and colleagues at the Cedars-Sinai Medical Center in Los Angeles, California, revealed findings related to the use of plasma glutamine as a prognostic biomarker for localized prostate cancer (see page 528). Prior research correlating elevated levels of glutamate with prostatic tumor tissue (1) as well as findings linking serum glutamate levels with Gleason score and aggressive disease (2) motivated the investigators to explore this as a potential measure of prognosis. Regardless of the evidence suggesting the association, samples from the cohort of 125 patients failed to indicate an association between plasma glutamine levels prior to radical prostatectomy and various clinicopathologic prognostic indicators.


Source Citation

Source Citation   

Gale Document Number: GALE|A679525831